US equities |
NVDA $238.90 ▲+2.12% SPCX $171.09 ▲+7.63% MU $1,063.96 ▼-1.02% TSLA $378.73 ▲+2.20% WBD $30.95 ▲+0.03% MSFT $525.18 ▲+1.48% AAPL $332.89 ▼-0.24% META $741.90 ▲+1.90%
FinancialContent

Articles published by Maze Therapeutics, Inc.

News headline image
Maze Therapeutics to Participate in Three Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Announces Appointments to Its Board of Directors
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Announces $150 Million Registered Offering
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Announces Positive Topline Data from Phase 2 HORIZON Trial of MZE829 Demonstrating the First Clinical Proof-of-Concept in Patients with Broad APOL1-Mediated Kidney Disease
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics to Participate in the TD Cowen 46th Annual Health Care Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics to Participate in the Guggenheim Emerging Outlook: Biotech Summit 2026
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Reports Third Quarter 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics to Present Additional Data Highlighting the Advancement of MZE829 and MZE782 Programs at ASN Kidney Week
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics to Participate in Four Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Appoints Industry Veteran Hervé Hoppenot as Chairman of the Board of Directors
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Appoints Misbah Tahir as Chief Financial Officer
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Reports Second Quarter 2025 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics to Participate in Two Upcoming Investor Conferences
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics to Participate in the Jefferies 2025 Global Healthcare Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Reports First Quarter 2025 Financial Results and Reiterates Upcoming Milestones
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics to Participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Highlights
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Doses First Patient in Phase 2 HORIZON Clinical Trial Evaluating MZE829 as a Potential Treatment for APOL1 Kidney Disease
From Maze Therapeutics, Inc.
Via GlobeNewswire
Tickers MAZE
News headline image
Maze Therapeutics Announces Pricing of Upsized Initial Public Offering
From Maze Therapeutics, Inc.
Via GlobeNewswire